trans-4-acetoxyproline | 4117-23-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: trans-4-acetoxyproline
• 英文别名: 4-(Acetyloxy)proline；4-acetyloxypyrrolidine-2-carboxylic acid
• CAS: 4117-23-1
• 化学式: C₇H₁₁NO₄
• 分子量: 173.169
• InChiKey: OQWHXHYZFMIILA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.8
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Process for producing optically active beta-trifluoromethyl-beta-hydroxycarbonyl compound
  申请人：Funabiki Kazumasa

  公开号：US20050119507A1

  公开（公告）日：2005-06-02

  The present invention provides a process for producing an optically active β-trifluoromethyl-β-hydroxycarbonyl compound represented by formula (3): comprising a step of reacting a fluoral equivalent represented by formula (1): with a carbonyl compound represented by formula (2): in the presence of an optically active amino acid or a derivative thereof.

  本发明提供了一种制备光学活性的β-三氟甲基-β-羟基羰基化合物的方法，该化合物由式（3）表示，包括在光学活性氨基酸或其衍生物的存在下，将由式（1）表示的芳醛等效物与由式（2）表示的羰基化合物反应的步骤。
• Urea derivative, process for producing the same, and use
  申请人：Kubo Keiji

  公开号：US20070093501A1

  公开（公告）日：2007-04-26

  The present invention provides a urea derivative or a salt thereof, which is useful as a therapeutic agent for thrombosis. The derivative is represented by Formula (I): wherein Cy is an aromatic hydrocarbon group which may be substituted or an aromatic heterocyclic group which may be substituted; R 1 is a hydrogen atom or a hydrocarbon group which may be substituted; V is —C(O)—, —S(O)—, or —S(O) 2 —; W is —N(R 2 )—, —O—, or a bond (wherein R 2 is a hydrogen atom or a hydrocarbon group which may be substituted); X is alkylene which may be substituted; Y is —C(O)—, —S(O)—, or —S(O) 2 —; Z is a bond, a chain hydrocarbon group which may be substituted, or —N═; ring A is a non-aromatic nitrogen-containing heterocyclic ring which may be substituted; ring B is a nitrogen-containing heterocyclic ring which may be substituted; and [Chemical formula 2] , are each independently a single bond or a double bond; provided that R 1 may be bonded to R 2 to form a non-aromatic nitrogen-containing heterocyclic ring and that R 2 may be bonded to a substituent of X to form a non-aromatic nitrogen-containing heterocyclic ring which may be substituted.

  本发明提供一种尿素衍生物或其盐，其作为治疗血栓症的治疗剂是有用的。该衍生物由公式（I）表示：其中，Cy是芳香族羟基烃基或芳香族杂环基，可以被取代；R1是氢原子或可以被取代的碳氢基团；V是-C（O）-，-S（O）-或-S（O）2-；W是-N（R2）-，-O-或键（其中R2是氢原子或可以被取代的碳氢基团）；X是可以被取代的烷基；Y是-C（O）-，-S（O）-或-S（O）2-；Z是键，可以被取代的链烃基团或-N═；环A是非芳香族含氮杂环环，可以被取代；环B是含氮杂环环，可以被取代；而[化学式2]都是单键或双键；但是，R1可以与R2连接形成非芳香族含氮杂环环，而R2可以与X的取代基连接形成可以被取代的非芳香族含氮杂环环。
• Peptide skeletal muscle relaxants
  申请人：BOC Health Care, Inc.

  公开号：EP0498941A2

  公开（公告）日：1992-08-19

  A method of achieving muscle relaxation comprising administering a polypeptide represented by the formula: wherein m is 0 or 1, n is 3-5, x is 0 or 2; R is lower alkyl, R₁ and R₂ are independently hydrogen, lower alkyl, allyl, propargyl, aryl lower alkyl, cyclo-lower alkyl lower alkyl and -COOR₃ or R plus one or both of R₁ and R₂ and the attached nitrogen form a 5- to 7-member heterocyclic ring, at least one AA is a basic amino acid, at least one AA is a lipophilic amino acid, Y is -NH₂ or -OR₄, R₃ is t-butyl, benzyl or fluorenylmethyl, and R₄ is lower alkyl, aryl lower alkyl and N-(lower alkyl)piperidyl lower alkyl, Z is a pharmaceutically acceptable anion and, wherein m and x are 0, pharmaceutically acceptable acid addition salts thereof. Diquaternary compounds within the above formula are novel.

  一种实现肌肉放松的方法，包括施用由式表示的多肽： 其中 m 为 0 或 1，n 为 3-5，x 为 0 或 2；R是低级烷基，R₁和R₂独立地是氢、低级烷基、烯丙基、丙炔基、芳基低级烷基、环低级烷基低级烷基和-COOR₃或 R加上R₁和R₂中的一个或两个以及所连接的氮形成5-7元杂环，至少一个AA是碱性氨基酸、至少一种 AA 是亲脂性氨基酸，Y 是-NH₂ 或-OR₄，R₃ 是叔丁基、苄基或芴甲基，R₄ 是低级烷基、芳基低级烷基和 N-(低级烷基)哌啶基低级烷基，Z 是药学上可接受的阴离子，其中 m 和 x 为 0，是药学上可接受的酸加成盐。上式中的二季化合物是新颖的。
• Peptide amides and amide dimers
  申请人：BOC Health Care, Inc.

  公开号：EP0498940A2

  公开（公告）日：1992-08-19

  Peptide amide and amide dimer muscle relaxants represented by the formulae: wherein: R is lower alkyl; R₁ and R₂ independently selected from the group consisting of hydrogen, lower alkyl, allyl, propargyl, aryl lower alkyl and cyclo-lower alkyl lower alkyl, or R plus one or both of R₁ and R₂, together with the nitrogen to which they are attached, form a heterocyclic ring having 5 to 7 member atoms; AA are independently selected from certain amino acids moieties; n is 2 to 4; x is independently 0 or 1; y is independently 1 or 2; z is 2 to 12; and and An⁻ is a pharmaceutically acceptable anion.

  肽酰胺和酰胺二聚体肌肉松弛剂的配方： 其中R是低级烷基；R₁和R₂独立地选自氢、低级烷基、烯丙基、丙炔基、芳基低级烷基和环低级烷基低级烷基组成的组，或R加上R₁和R₂中的一个或两个，连同它们所连接的氮，形成一个具有5至7个成员原子的杂环；AA 独立地选自某些氨基酸分子；n 为 2 至 4；x 独立地为 0 或 1；y 独立地为 1 或 2；z 为 2 至 12；An- 为药学上可接受的阴离子。
• Cyclic peptides and use thereof
  申请人：TAKEDA CHEMICAL INDUSTRIES, LTD.

  公开号：EP0528312A2

  公开（公告）日：1993-02-24

  Disclosed are (1) a cyclic hexapeptide represented by formula [I] or a salt thereof: wherein X and Y each represent a-amino acid residues, A represents a D-acidic-a-amino acid residue, B represents a neutral-a-amino acid residue, C represents an L-a-amino acid residue and D represents a D-a-amino acid residue having an aromatic ring group; and (2) a pharmaceutical composition comprising the peptide represented by formula [I] or a pharmaceutically acceptable salt thereof as an active ingredient.

  公开了 (1) 由式 [I] 表示的环六肽或其盐： 其中 X 和 Y 分别代表 a-氨基酸残基，A 代表 D-酸性-a-氨基酸残基，B 代表中性-a-氨基酸残基，C 代表 L-a-氨基酸残基，D 代表具有芳香环基的 D-a-氨基酸残基；以及 (2) 一种药物组合物，其活性成分包含式 [I] 所代表的肽或其药学上可接受的盐。